After vaccine scandal, China acts on those responsible for Juxin explosion

By PharmaCompass

2018-08-30

Impressions: 292 Article

On December 9, 2017, an explosion occurred at Lianyungang Juxin Biotechnology Co Ltd in the Lianyungang Chemical Industry Park of Jiangsu Province.

The explosion claimed 10 lives and according to the investigative report by the Jiangsu government, the energy released by the blast was equivalent to 14.15 metric tons of trinitrotoluene (TNT). The blast caused a direct economic loss of 48.7 million yuan (US$ 7 million).

In a crackdown against those responsible for the explosion, the Ministry of Emergency Management under the Chinese government said that the company has been fined 5 million yuan (US$ 730,750). Moreover, its production permit has been revoked and its leaders will be prosecuted.

The report said 45 people and 10 companies were responsible for the blast, and that 13 people will be prosecuted criminally, including Juxin's general manager and production safety director.

According to the report, one of the reasons for the blast was Juxin's failure to ensure its unit’s design and equipment installation complied with legal safety requirements.

The local government of Guannan and its management committee for the chemical industry park were also found not to pay enough attention to safety and the report said it too should be held responsible. The report also found that government departments in charge of safety supervision and project management also failed to perform their duties.

Before the explosion, Lianyungang Juxin had a leading position in the production of pesticide intermediates such as m-dinitrobenzene, m-dichlorobenzene, m-hydroxybenzoic acid and phosphorus pentasulfide.

After its recent crackdown against individuals responsible for the vaccine scandal, China continued action against responsible individuals, within companies and the government, in order to ensure that safety standards are met is likely to significantly impact China’s approach towards manufacturing in the future.

The PharmaCompass Newsletter – Sign Up, Stay Ahead

Feedback, help us to improve. Click here

Image Credit : #Phisper Infographic by SCORR MARKETING & PharmaCompass is licensed under CC BY 2.0

“ The article is based on the information available in public and which the author believes to be true. The author is not disseminating any information, which the author believes or knows, is confidential or in conflict with the privacy of any person. The views expressed or information supplied through this article is mere opinion and observation of the author. The author does not intend to defame, insult or, cause loss or damage to anyone, in any manner, through this article.”

NEWS

DRUGS & DEVELOPMENTS

MARKET INTEL by PharmaCompass